Phase I/II Study of SBRT and GC4711 for Centrally Located or Large NSCLC

Stopped Development GC4711 was halted after the lead study in pancreatic cancer was stopped early due to meeting the requirements of a futility analysis

Conditions

• SBRT
• NSCLC
• Non-metastatic

Interventions

• DRUG: GC4711 +SBRT
• DRUG: Placebo +SBRT

Sponsor

Galera Therapeutics, Inc.